Just to be clear—The LLY post by jbog (#msg-172218315) was about an injected triple-MoA drug called Retatrutide that is in phase-2; the LLY post by me (#msg-172182849) was about an oral GLP-1 called Orforglipron that is in phase-3.
There are so many injected and oral incretin-mimetic and incretin-receptor-agonist compounds in development that one needs a scorecard to keep track of them all.
Market Data 
Markets 
AI
